Inhibrx Net Interest Income from 2010 to 2026
| INBX Stock | USD 83.91 2.38 2.92% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter -2.9 M | Current Value -3.1 M | Quarterly Volatility 6.7 M |
Check Inhibrx Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Selling General Administrative of 154.4 M or Selling And Marketing Expenses of 202.4 K, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0522 or PTB Ratio of 1.58. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Biosciences Valuation or Volatility modules.
Inhibrx | Net Interest Income | Build AI portfolio with Inhibrx Stock |
The evolution of Net Interest Income for Inhibrx Biosciences provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Inhibrx Biosciences compares to historical norms and industry peers.
Latest Inhibrx Biosciences' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Inhibrx Biosciences over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Inhibrx Biosciences' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Inhibrx Net Interest Income Regression Statistics
| Arithmetic Mean | (16,910,999) | |
| Coefficient Of Variation | (39.66) | |
| Mean Deviation | 4,960,943 | |
| Median | (19,923,000) | |
| Standard Deviation | 6,707,614 | |
| Sample Variance | 45T | |
| Range | 17.4M | |
| R-Value | 0.66 | |
| Mean Square Error | 27.1T | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 877,203 | |
| Total Sum of Squares | 719.9T |
Inhibrx Net Interest Income History
About Inhibrx Biosciences Financial Statements
Inhibrx Biosciences investors use historical fundamental indicators, such as Inhibrx Biosciences' Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -2.9 M | -3.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inhibrx Stock Analysis
When running Inhibrx Biosciences' price analysis, check to measure Inhibrx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences is operating at the current time. Most of Inhibrx Biosciences' value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences' price. Additionally, you may evaluate how the addition of Inhibrx Biosciences to your portfolios can decrease your overall portfolio volatility.